TY - JOUR
T1 - Effects of stem cell transplantation in patients with peripheral T-cell lymphoma not otherwise specified and angioimmunoblastic T-cell lymphoma
AU - For the Fukuoka Blood and Marrow Transplantation Group
AU - Yamasaki, Satoshi
AU - Yoshida, Shuro
AU - Kato, Koji
AU - Choi, Ilseung
AU - Imamura, Yutaka
AU - Kohno, Kentaro
AU - Henzan, Hideho
AU - Tanimoto, Kazuki
AU - Ogawa, Ryosuke
AU - Suehiro, Youko
AU - Miyamoto, Toshihiro
AU - Eto, Tetsuya
AU - Ohshima, Koichi
AU - Akashi, Koichi
AU - Iwasaki, Hiromi
N1 - Funding Information:
No funding or sponsorship was received for this study or publication of this article. The article processing charges were funded by the authors.
Funding Information:
Koji Kato: Consulting or advisory role with AbbVie, AstraZeneca, Celgene, Chugai, Eisai, Janssen, and Novartis. Honoraria from Chugai, Takeda, MSD, Kyowa-Kirin, Janssen, Celgene, Ono, Dainippon-Sumitomo, AbbVie, Novartis. Research funding from Chugai, Takeda, Kyowa-Kirin, Abbvie, Eisai, Janssen, Novartis, Mundi, AstraZeneca, Celgene, Ono, MSD, and Otsuka. The other authors declare that there are no competing financial interests regarding this article.
PY - 2020/7/1
Y1 - 2020/7/1
N2 - The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. All PTCL-NOS and AITL diagnoses were reconfirmed by an experienced hematopathologist. Median age at PTCL-NOS and AITL diagnoses in the SCT group was younger than that in the no SCT group. Significant risk factors for lower overall survival were intermediate–high and high-risk international prognostic indexes in PTCL-NOS patients (P = 0.0052), and a > 2 modified prognostic index for T-cell lymphoma (P = 0.0079) and no SCT (P = 0.028) in AITL patients. Autologous or allogeneic SCT compared with no SCT in AITL patients resulted in 3-year overall survival of 68.6% and 100% vs. 57.2% (P = 0.018). Strategies should be developed to improve selection of PTCL-NOS and AITL patients suitable for SCT and/or additional novel therapies.
AB - The effects of stem cell transplantation (SCT) in patients with peripheral T-cell lymphoma not otherwise specified (PTCL-NOS) and angioimmunoblastic T-cell lymphoma (AITL) remain controversial. We analyzed the feasibility of SCT and risk factors associated with outcomes of PTCL-NOS and AITL patients to identify the potential clinical efficacy of SCT. We retrospectively analyzed the data of PTCL-NOS (n = 83) and AITL (n = 112) patients who received autologous (n = 10 and 16, respectively) or allogeneic (n = 12 and 4, respectively) SCT, or no SCT (n = 61 and 92, respectively) between 2008 and 2018. All PTCL-NOS and AITL diagnoses were reconfirmed by an experienced hematopathologist. Median age at PTCL-NOS and AITL diagnoses in the SCT group was younger than that in the no SCT group. Significant risk factors for lower overall survival were intermediate–high and high-risk international prognostic indexes in PTCL-NOS patients (P = 0.0052), and a > 2 modified prognostic index for T-cell lymphoma (P = 0.0079) and no SCT (P = 0.028) in AITL patients. Autologous or allogeneic SCT compared with no SCT in AITL patients resulted in 3-year overall survival of 68.6% and 100% vs. 57.2% (P = 0.018). Strategies should be developed to improve selection of PTCL-NOS and AITL patients suitable for SCT and/or additional novel therapies.
UR - http://www.scopus.com/inward/record.url?scp=85083451828&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85083451828&partnerID=8YFLogxK
U2 - 10.1007/s12185-020-02879-w
DO - 10.1007/s12185-020-02879-w
M3 - Article
C2 - 32297159
AN - SCOPUS:85083451828
VL - 112
SP - 74
EP - 83
JO - International Journal of Hematology
JF - International Journal of Hematology
SN - 0925-5710
IS - 1
ER -